Biostem Technologies (BSEM) Planet MicroCap Las Vegas 2026 summary

Corporate Strategy and Recent Developments

• Completed transformative acquisition of BioTissue, expanding into hospital and surgical markets and increasing TAM by $8 billion, with integration of GPO contracts and direct sales force expansion.

• Integration of BioTissue assets underway, with plans to bring manufacturing in-house by January 2027 to boost gross margins from mid-50s to mid-70s.

• Filed Form-10 with the SEC and Nasdaq application, aiming for uplisting by summer after completing KPMG audits for 2024 and 2025.

• Strengthened balance sheet by retiring debt, closing $2.5 million PIPE with an institutional investor, and expanding the leadership team.

• Analyst coverage initiated with a $7 price target and focus on continued growth.

Product Portfolio and Market Positioning

• Added CryoTek and SteriTek technologies, Clarix/Neox surgical products, and six perinatal-derived allograft brands through BioTissue acquisition.

• Expanded sales force from 15 to 35 W-2s, plus 30 independent reps, with plans to reach 40+ direct reps and increase ISA coverage.

• Shifted payer mix from Medicare to commercial payers, reducing reimbursement risk and expanding hospital market access.

• Portfolio supported by 68 issued US patents, 81 pending, and over 400 publications; new product launches and a pending 510(k) micronized product in the pipeline.

• Manufacturing facility operating at 15-20% capacity, with room for growth and efficiency gains post-tech transfer.

Financial Outlook and Guidance

• Q1 revenue of $6.1 million and 61% gross margin; cash and equivalents at $13.7 million.

• Issued 2024 top-line guidance of $25–$29 million, with BioTissue expected to contribute the majority of revenue.

• Acquired assets generated $29 million in 2025, with positive adjusted EBITDA and cashflow.

• Anticipates second-half revenue growth due to seasonality in commercial payer base and plans to expand direct sales reps to 40.

• Transition period in 1H26 due to CMS payment changes, but efficient manufacturing and technology transfer expected to sustain margins.